Clinical Trial

A Study of DS-1001b in Patients With Chemotherapy- and Radiotherapy-Naive IDH1 Mutated WHO Grade II Glioma

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This Phase 2 study is conducted to assess the efficacy and safety of DS-1001b in patients with chemotherapy- and radiotherapy-naive IDH1 mutated WHO grade II glioma.
Protocol Amendment History 12 amendments
This ClinicalTrials.gov record has been amended 12 times since 2020-07-02; most recent amendment 2026-03-17.
Status change: Recruiting → Active, Not Recruiting 2021-01-29
Status change: Not Yet Recruiting → Recruiting 2020-07-31
Trial Details
NCT Number NCT04458272
Lead Sponsor Daiichi Sankyo Co., Ltd.
Conditions WHO Grade II Glioma
Enrollment 25 participants
Start Date 2020-07-08
Primary Completion 2023-03-10 (estimated)
Study Completion 2026-08-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-20